Skip to content

Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic

Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02818803
Enrollment
40
Registered
2016-06-30
Start date
2016-01-31
Completion date
2016-06-30
Last updated
2016-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candidiasis, Oral, Stomatitis, Denture

Keywords

propolis, therapeutic, miconazole, denture stomatitis

Brief summary

The purpose of this study is to evaluate the efficacy and safety of propolis on the treatment of oral candidiasis, more specifically denture stomatitis. Half of participants will receive a standardized-propolis (EPP-AF®) gel formulation while the other half will receive miconazole gel, both for oral use.

Interventions

OTHERPropolis

Sponsors

Financiadora de Estudos e Projetos
CollaboratorOTHER
University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elderly patients with denture stomatitis

Exclusion criteria

* Recent use of anti fungals or antibiotics(2 months or less), dementia

Design outcomes

Primary

MeasureTime frameDescription
Change from Newton Score at 14 daysDay 14Clinical assessment of buccal lesions localized at hard palate. The score utilized to measure the intensity of lesions will be Newton classification (I - punctate in the palate; II - extensive smooth reddened appearance; III -extensive reddening with hyperplastic growth) and the outcome will be the reduction of Newton's score comparing day 1 with day 14.

Secondary

MeasureTime frameDescription
Assessment of gel acceptabilityDay 7Application of hedonic scale on day 7
Assessment of adverse eventsDay 7 and 14Questioning about rise of adverse events on days 7 and 14
Anti fungal activityDay 1 and 14Colony forming unit count (CFU/mL) on days 1 and 14

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026